CVS HEALTH Corp: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Feb 8, 2023 and accepted by EDGAR at Feb 8, 2023, 06:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $322.47bn | us-gaap:Revenues |
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | $196.89bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 12 months2022-01-01 to 2022-12-31 | $7.75bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $2.29bn | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $1.46bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | $4.15bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | $3.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | $3.16 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 1,323,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | $16.18bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $2.73bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2022-01-01 to 2022-12-31 | $2.91bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2022-01-01 to 2022-12-31 | $3.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-12-31 | $12.95bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $65.68bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $228.28bn | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $69.74bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $156.96bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $71.02bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-23-000009. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.